They really do need a placebo if they truly want to prove the results are from Leronlimab. But in this case it's ultimately a matter of life or death so the placebo patients can and will get moved to Leronlimab if they worsen. At least according to NP from previous interviews. There must be some sort of predetermined length of time or symptom onset that triggers them to be given Leronlimab. I guess it will still provide data that patients not on leronlimab were getting worse but then the option is still there to switch them over and help them. So best of both worlds? All of this is me interpreting the interviews and PRs, I don't really know any of this for sure. I just hope I'm at least partly right and none of these patients would progress in symptoms/disease very far before getting leronlimab.